TokenPost·
Novartis Says AI Could Cut Drug Development From 12 Years to Eight

CEO Vasant Narasimhan said AI is speeding candidate discovery and clinical operations. Novartis is targeting a higher success rate for drugs entering human testing.
Every crypto headline. One feed. Updated every minute.

CEO Vasant Narasimhan said AI is speeding candidate discovery and clinical operations. Novartis is targeting a higher success rate for drugs entering human testing.